Exonic Disruption Facilitates Antiviral CRISPR-Cas9 Activity for Multistrain HIV-1 Elimination
Authors:
- Jonathan HerskovitzJHJonathan Herskovitz
- Mahmudul HasanMHMahmudul Hasan
- Milankumar PatelMPMilankumar Patel
- Wilson R. BlombergWBWilson R. Blomberg
- Jacob D. CohenJCJacob D. Cohen
- Jatin MachhiJMJatin Machhi
- Evan A. SchroderESEvan A. Schroder
- JoEllyn McMillanJMJoEllyn McMillan
- Channabasavaiah B. GurumurthyCGChannabasavaiah B. Gurumurthy
- Bhavesh D. KevadiyaBKBhavesh D. Kevadiya
- Howard E. GendelmanHGHoward E. Gendelman
Preprint
Abstract
A barrier to HIV-1 cure rests in the persistence of proviral DNA in infected CD4+ leukocytes. The high mutation rate of HIV-1 gives rise to numerous circulating strains with increased capacity for immune evasion and antiretroviral drug resistance. To facilitate viral elimination while accounting for this diversity, we propose genetic inactivation of proviral DNA with CRISPR-spCas9. We designed a library of “mosaic gRNAs” against a HIV-1 consensus sequence constructed from 4004 clinical strains, targeting the viral transcriptional regulator tat. Testing in 7 HIV-1 transmitted founder strains led, on average, to viral reductions of 82% with tandem TatD and TatE (TatDE) treatment. No off-target cleavages were recorded. Lentiviral transduction of TatDE attenuated latency reversal by 94% in HIV-infected, transcriptionally silent ACH2 T cells. In all, TatDE guide RNAs successfully disrupted 5 separate HIV-1 exons ( tat 1-2 / rev 1-2 / gp41 ) providing a pathway for CRISPR-directed HIV-1 cure therapies. Significance Statement: Over 38 million individuals worldwide are infected with HIV-1, which necessitates lifelong dependence on antiretroviral therapy (ART) to prevent viral replication that leads to AIDS. Efforts to rid hosts of HIV-1 are limited by the virus’ abilities to integrate proviral DNA in nuclei, mutate their genomes, and lay dormant for decades during ART treatment. We developed mosaic guide RNAs, TatD and TatE, for CRISPR-Cas9 that recognize the majority of known HIV-1 strains and inactivate 94% of proviral DNA in latently infected cells. Tandem TatDE-CRISPR inactivation of 5 viral exons (t at 1-2 , rev 1-2 , and gp41 ), which blocked HIV-1 replication for 28 days in CD4+ T cells without unwanted editing to the host genome, may serve as a viable strategy for HIV cure.Keywords
All Related Versions
- Published version: EBioMedicine, 73, 103678.
This publication has 40 references indexed in Scilit:
- Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort studyThe Lancet HIV, 2020
- Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case reportThe Lancet HIV, 2020
- Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV VariantsmBio, 2020
- Advances in Developing CAR T-Cell Therapy for HIV CureFrontiers in Immunology, 2020
- Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus InfectionJournal of Virology, 2019
- Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing PlatformCell, 2019
- Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse modelScience Translational Medicine, 2019
- Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeysNature, 2018
- Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized miceJournal of Clinical Investigation, 2018
- Control of HIV despite the Discontinuation of Antiretroviral TherapyNew England Journal of Medicine, 1999